Explore / Peer-reviewed article
Peer-reviewed article

Optimized Parenteral and Intranasal Formulations of Tryptamine Psychedelics for Rapid-Acting Antidepressant Therapy.

Kargbo RBiD

ACS medicinal chemistry lettersMay 16, 2025United States2 citationsDOI: 10.1021/acsmedchemlett.5c00265

Abstract

Innovative formulations of N,N-dimethyltryptamine (DMT) and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) enable parenteral and intranasal delivery, respectively. These delivery systems overcome limitations of poor bioavailability and rapid metabolism, offering rapid-onset, short-duration therapeutic effects. The compositions support controlled psychedelic interventions for psychiatric conditions such as treatment-resistant depression while optimizing tolerability, scalability, and clinical utility.

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

DMT5-MeO-DMTDepression

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.